Quarterly report pursuant to Section 13 or 15(d)


3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  



Historically, stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, with expiration 10 years from the date they are granted, and generally vest over a one to three-year period for employees and members of the Board. Upon exercise, new shares will be issued by the Company. The restricted shares and restricted stock units (“RSUs”) granted to Board members and employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.


The following table provides the weighted average assumptions used in determining the fair value of the stock option awards granted during the three-month period ended March 31, 2022. There were no stock option awards issued in the three months ended March 31, 2023.


    March 31, 2022  
Risk-free interest rate     1.75 %
Expected life     6.0 years  
Expected volatility     129.93 %
Dividend yield     -  


The Company recognized approximately $0.2 million and $0.3 million of stock-based compensation expense within continuing operations during the three-month periods ended March 31, 2023 and 2022, respectively. The following table has a breakout of stock-based compensation expense from continuing operations by line item.



    2023     2022  
    Three Months Ended  
    March 31,  
    2023     2022  
Cost of revenue   $ 14     $ 27  
Sales and marketing     30       44  
Research and development     -       -  
General and administrative*     148       232  
Total stock compensation expense   $ 192     $ 303  


* Includes ESPP expense in 2022